| Excerpt | Reference |
|---|
| "Duodenal carcinoids are indolent, especially when small and localized to the submucosa." | ( Burke, AP; Federspiel, BH; Helwig, EB; Shekitka, KM; Sobin, LH, 1990) |
| "Goblet-cell carcinoids are particular mucus-producing tumors combining features of typical carcinoids and adenocarcinomas." | ( Heitz, PU; Höfler, H; Klöppel, G, 1984) |
| "Metastasized carcinoids are often diagnosed by measuring 5-hydroxyindoleacetic acid excretion in the urine." | ( De Vries, EG; Kema, IP; Kleibeuker, JH; Mulder, NH; Sleijfer, DT; Slooff, MJ; Verschueren, RC; Willemse, PH, 1993) |
| "Pulmonary carcinoids are rarely associated with carcinoid syndromes and even less commonly with carcinoid crisis." | ( Karmy-Jones, R; Vallières, E, 1993) |
| "Carcinoids are in general thought to be radioresistent, and have not been subjected to radiation therapy, except for palliative purposes." | ( Bratlie, J; Hanssen, LE; Hellesnes, J; Jacobsen, MB; Reitan, JB, 1993) |
| "Bronchial carcinoid is the most frequent cause of Cushing's syndrome due to ectopic ACTH production." | ( Casadio, C; Cianci, R; Filosso, PL; Mazza, E; Molinatti, M; Oliaro, A; Oliveri, F; Porrello, C; Rastelli, M; Ruffini, E, 1995) |
| "Ovarian metastatic carcinoids are rare neoplasms that show prominent fibrosis of tumor stroma and are often associated with peritoneal carcinomatosis." | ( Capella, C; Dionigi, A; Facco, C; La Rosa, S; Riva, C; Uccella, S, 1998) |
| "Primary thymic carcinoids are rare tumors in which the tumor cells retain functional somatostatin receptors." | ( Aguilö, F; Flores, C; Silva, F; Vázquez, G; Vázquez-Sellés, J, 1999) |
| "Gastric carcinoids are of increasing clinical concern because they may develop in hypergastrinemic states, especially with the increased chronic use of potent acid suppressants that can cause hypergastrinemia." | ( Doppman, JL; Gibril, F; Jensen, RT; Lubensky, IA; Peghini, PL; Reynolds, JC; Roy, PK, 2000) |
| "Gastrointestinal carcinoids are derived from the diffuse intestinal endocrine system and may produce amines and many peptides, including serotonin, chromogranin A (CGA), and tachykinins." | ( Tomita, T, 2001) |
| "Gastric carcinoids are strongly associated with chronic atrophic gastritis A, and it is suggested that hypergastrinemia plays a critical role in development of gastric carcinoids." | ( Fujioka, T; Honda, S; Kagawa, J; Kodama, M; Murakami, K; Sato, R, 2002) |
| "Biliary carcinoids are rare with fewer than 30 cases reported in the English literature." | ( Eckhauser, FE; Pawlik, TM; Shah, S, 2003) |
| "Carcinoid is one of the most common endocrine active tumours of the gastrointestinal tract." | ( Cáslavský, J; Chmelík, J; Dastych, M; Senkyrík, M; Starý, K; Zboril, V, 2003) |
| "Gastric carcinoid is a rare tumour that is associated with chronic atrophic gastritis in the majority of cases." | ( de Bree, E; Kofteridis, D; Papadimitraki, E; Skordilis, P; Tsiftsis, DD; Tzardi, M, 2003) |
| "Gastric carcinoids are indolent tumors occurring with increasing frequency in patients with pernicious anemia." | ( Barroso, A; Jordan, PH; Sweeney, J, 2004) |
| "Duodenal carcinoids are uncommon tumors with a wide clinical-pathologic spectrum." | ( Abbott, RM; Levy, AD; Sobin, LH; Taylor, LD, 2005) |
| "Unless carcinoid are in general slow-growing tumors, some cases could be frankly malignant." | ( Aristu, J; Bastarrika, G; Chopitea, A; García-Foncillas, J; González Cao, M; Martín Algarra, S, 2006) |
| "Carcinoids are malignant neuroendocrine tumors consisting of a spectrum of neoplasms from low-grade typical carcinoid to high-grade small cell carcinoma." | ( Dham, A; Dudek, AZ; Truskinovsky, AM, 2008) |
| "Carcinoid is a rare gastrointestinal tumor, with an incidence varying from 1 to 2." | ( Cruz, RP; Gomes Thomé, G; Mottin, CC; Padoin, AV, 2009) |
| "Carcinoids are neuroendocrine (NE) tumors with limited treatment options." | ( Adler, JT; Chen, H; Ju, J; Kunnimalaiyaan, M; Li, W; Luo, Y; Pinchot, SN; Shen, B, 2009) |
| "Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea and flushing, can be debilitating and occasionally life-threatening." | ( Anthony, L; Baulieu, JL; Benson, AB; Borson-Chazot, F; Bouterfa, H; Bushnell, DL; Connolly, M; Grossman, AB; Hicks, RJ; Kacena, KA; LaFrance, N; Li, Y; Menda, Y; O'Dorisio, MS; O'Dorisio, TM; Oberg, K; Pauwels, SA; Van Cutsem, E, 2010) |
| "Thymic carcinoids are aggressive and present at an advanced stage." | ( Dutta, R; Jindal, T; Julka, PK; Kaushal, S; Kumar, A; Kumar, R; Mathur, SR; Suri, V, 2010) |
| "Carcinoids are neuroendocrine (NE) tumors with limited treatment options." | ( Chen, H; Cook, MR; Jaskula-Sztul, R; Kunnimalaiyaan, M; Ning, L; Peters, NR; Pinchot, SN, 2011) |
| "Gastric type I carcinoid is a rare neoplasm, deriving from enterochromaffin-like cells (ECL), mainly affecting women with autoimmune gastritis." | ( Basso, D; Betterle, C; Cazzagon, N; Farinati, F; Maddalo, G; Martini, C; Mescoli, C; Nitti, D; Rugge, M; Tieppo, C; Zorzetto, V, 2011) |
| "Pulmonary carcinoids are histologically classified into typical and atypical." | ( Dutta, R; Jindal, T; Kumar, A; Kumar, R; Malhotra, A; Meena, M; Venkitaraman, B, 2011) |
| "Type 1 gastric carcinoids are usually indolent and have a metastasis rate of less than 2%, even with tumors larger than 2 cm." | ( Jani, N; Senadhi, V, 2011) |
| "Ovarian carcinoid is a rare tumor accounting for approximately 0." | ( Miura, J; Shoji, T; Sugiyama, T; Takatori, E; Takeuchi, S; Yoshizaki, A, 2012) |
| "The term carcinoid is commonly used for the more benign variants of these neoplasms." | ( Grozinsky-Glasberg, S; Pavel, M, 2012) |
| "Carcinoids are neuroendocrine malignancies characterized by their overproduction of various bioactive hormones that lead to the carcinoid syndrome." | ( Chen, H; Harrison, AD; Kunnimalaiyaan, M; Kunnimalaiyaan, S; Simon, K; Somnay, Y, 2013) |
| "Bronchial carcinoids are pulmonary neuroendocrine cell-derived tumors comprising typical (TC) and atypical (AC) malignant phenotypes." | ( Adeli, K; Cutz, E; Islam, SS; Kumar, S; Mokhtari, RB; Yazdanpanah, M; Yeger, H, 2013) |
| "Ovarian carcinoid is a rare neoplasm of low-grade malignancy occurring within a dermoid cyst or mucinous tumor, predominantly in perimenopausal women." | ( Horikawa, M; Kaji, T; Miyai, K; Shinmoto, H; Soga, S, 2014) |
| "Carcinoids are slow-growing neuroendocrine tumors (NETs) that are characterized by hormone overproduction; surgery is currently the only option for treatment." | ( Bugni, TS; Chen, H; Cho, H; Dammalapati, A; Harrison, AD; Jaskula-Sztul, R; Kwon, GS; Wyche, TP, 2014) |
| "Because gastric carcinoids are an orphan disease, and nonclinical and healthy volunteer studies support treatment with netazepide, a gastrin/CCK2 antagonist, netazepide has been designated an orphan medicinal product in Europe and the USA for development as targeted treatment for gastric carcinoids." | ( Boyce, M; Thomsen, L, 2015) |
| "Carcinoids are neuroendocrine neoplasms that cause significant morbidity and mortality and for which few effective therapies are available." | ( Chen, H; Dull, BZ; Eide, J; Jaskula-Sztul, R; Somnay, YR, 2015) |
| "Gastric carcinoids are slow growing neuroendocrine tumours arising from enterochromaffin-like (ECL) cells in the corpus of stomach." | ( Choi, EK; Hayes, MM; Kang, AJ; Merchant, JL; Sundaresan, S, 2017) |
| "Pulmonary carcinoids are rare low-grade malignant tumors, which arise from the neuroendocrine system." | ( Prosch, H, 2017) |
| "Bronchopulmonary carcinoids are low-grade tumors for which the standard treatment is surgical resection." | ( Maki, Y; Nakata, K; Nishimura, R; Sugawara, Y; Sugimoto, R; Teramoto, N; Ueno, T; Yamashita, M, 2019) |
| "Typical carcinoid is usually slow growing, not associated with plasma progastrin releasing peptide (ProGRP) elevation." | ( Azuma, D; Hara, K; Inoue, K; Iwata, T; Kohara, M; Morii, E; Nagai, Y; Nakatsuka, S; Yamamoto, A; Yamamoto, T; Yamamuro, T, 2018) |
| "Carcinoid is a subtype of neuroendocrine tumor, a rare group of tumors that are known to express somatostatin receptor 2." | ( Broski, SM; Clark, M; Nathan, M, 2019) |
| "Bronchial carcinoids are neuroendocrine tumors that present as typical (TC) and atypical (AC) variants, the latter being more aggressive, invasive and metastatic." | ( Baluch, N; Bayat Mokhtari, R; Cheng, HL; Das, B; Kumar, S; Morgatskaya, E; Muscarella, LA; Sparaneo, A; Yeger, H; Zhao, S, 2019) |
| "Bronchial carcinoids are uncommon tumors accounting for 20 to 30% of all neuroendocrine tumors and about 1-2% of all cancers of pulmonary origin." | ( Halfdanarson, TR; Leventakos, K; Molina, JR; Uprety, D, 2020) |
| "Thymic atypical carcinoids are extremely rare tumors and have a poor prognosis owing to their aggressive clinical course." | ( Hagui, E; Haneda, H; Nakano, T; Okuda, K; Sakane, T, 2023) |
| Excerpt | Reference |
|---|
| "14 patients with metastatic carcinoid tumour were treated with recombinant interferon alfa 6-30 x 10(6) IU weekly for 3-25 (median 6." | ( Gröhn, P; Joensuu, H; Kumpulainen, E, 1992) |
| "A phase II trial of chemotherapy in carcinoid and islet cell pancreatic tumours has been conducted with the FAP protocol: 5-fluorouracil 400 mg/m2 per day (5-FU) for 3 days, 50 mg/m2 doxorubicin on day 2, and 90 mg/m2 cisplatin on day 2, repeated every 4 weeks." | ( Droz, JP; Ducreux, M; Kac, J; Oliveira, J; Rougier, P; Theodore, C, 1991) |
| "Resection of small bowel carcinoid tumor is indicated even when the liver is involved by diffuse metastases to prevent the risk of small bowel occlusion, and to promote hepatic chemoembolization as subsequent therapy against the carcinoid syndrome and metastatic spread." | ( Landraud, R; Partensky, C; Souquet, JC; Velecela, E, 1990) |
| "A total of 13 patients with metastatic carcinoid tumour, paraganglioma, or unclassified "apudoma" were treated with single-agent carboplatin at a dose of 400 mg/m2 given by intravenous infusion every 4 weeks, on the basis that this new agent shows high activity against small-cell lung cancer that also has "apudoma" characteristics." | ( Jodrell, DI; Smith, IE, 1990) |
| "Eight patients with metastatic carcinoid tumor, seven of whom had symptoms of the carcinoid syndrome, were treated with either human leukocyte interferon (seven patients) or recombinant alpha-interferon (IFN alpha-2b) (one patient) at doses of 4." | ( Järvinen, H; Pelkonen, R; Salmela, P; Sane, T; Sjöblom, SM; Välimäki, M, 1991) |
| "The case of a carcinoid tumor with a hepatic metastasis is presented and its clinical as well as its biochemical and its morphological results are evaluated after treatment with octreotide over a seven months period." | ( Goñi, F; Goñi, MJ; González, A; Llorente, I; Moncada, E; Monreal, M; Oleaga, A; Yoldi, A, 1991) |
| "Seventeen patients with malignant carcinoid tumour, ten of whom had the malignant carcinoid syndrome, were treated with recombinant alpha-2b interferon by subcutaneous injection (3 MU per dose) three times per week for a median of 12 weeks (range 4-48)." | ( Basser, RL; Fox, RM; Green, MD; Lieschke, GJ; Sheridan, WP, 1991) |
| "Neuroendocrine cell (carcinoid) tumours have been reported in the acid-secreting part of the stomach of rodents after long-term administration of a range of potent chemically diverse antisecretory agents." | ( Selway, SA, 1990) |
| "Gastric carcinoids were found to develop in experimental animals as a consequence of continuous long-term administration of several of these highly effective anti secretory drugs." | ( Håkanson, R; Sundler, F, 1990) |
| "Thirty-six patients with malignant carcinoid tumors were treated with human leukocyte interferon (IFN) im at doses of 3-6 megaunits/day." | ( Alm, G; Jonsdottir, B; Lind, E; Lundqvist, G; Magnusson, A; Norheim, I; Oberg, K; Wide, L; Wilander, E, 1986) |
| "Fundic argyrophil carcinoid tumors developed in the course of a 5-year continuous treatment with high dosages of H2-antagonists in a well-documented case of Zollinger-Ellison syndrome with primary hyperparathyroidism, high basal acid output, and serum gastrin." | ( Bonfils, S; Bonnefond, A; Labeille, D; Lehy, T; Mignon, M; Ruszniewski, P, 1987) |
| "Thirty-one patients with malignant carcinoid tumors were treated with streptozocin--alone (n = 7) or in combination with FU (n = 24)." | ( Lundqvist, G; Norheim, I; Oberg, K; Wide, L, 1987) |
| "Twenty patients with malignant carcinoid tumors were treated for 6 months with recombinant interferon alfa-2b (IFN alpha-2b; Intron-A; Schering Corp." | ( Alm, G; Lundqvist, G; Magnusson, A; Oberg, K; Theodorsson, E; Wide, L; Wilander, E, 1989) |
| "Past case reports on the coexistence of carcinoid tumors and adenocarcinomas in the digestive tract suggest that the tumor cells in our case are also derived from primitive or stem cells of endodermal origin and expressed unusual differentiation in the course of treatment." | ( Midorikawa, O; Morikawa, S; Ohtsuki, H; Okada, H; Sakaguchi, H, 1988) |
| "The severity of the carcinoid flush in all the patients was reduced by administration of the analogue." | ( Balks, HJ; Conlon, JM; Creutzfeldt, W; Stöckmann, F, 1989) |
| "This gastrin-carcinoid sequence is unlikely to occur in man with an omeprazole dosage recommended for treatment of peptic diseases." | ( Arnold, R; Koop, H, 1989) |
| "No focal hyperplasias or carcinoids were present after 200 mg/kg/day po treatment." | ( Betton, GR; Buckley, P; Dormer, CS; Pert, P; Price, CA; Wells, T, 1988) |
| "Six adults were treated, three with a carcinoid, two malignant pheochromocytoma and one medullary thyroid carcinoma." | ( de Kraker, J; Evans, AE; Green, A; Hayes, A; Hoefnagel, CA; Voûte, PA, 1987) |
| "Serotonin (5-HT)-producing human carcinoid tumors have been successfully transplanted to the anterior eye chamber of cyclosporine treated rats." | ( Ahlman, H; Dahlström, A; Ericson, LE; Nilsson, O; Skolnik, G, 1986) |
| "Serotonin (5-HT)-producing human carcinoid tumors of midgut origin were transplanted to the anterior eye chamber of cyclosporine-treated rats." | ( Ahlman, H; Dahlström, A; Grönstad, KO; Nilsson, O; Skolnik, G, 1987) |
| "Thirty patients with symptoms of the carcinoid syndrome and other symptoms not controlled by pharmacological agents were analysed with respect to the value of various treatment measures used." | ( Johnson, PJ; Melia, WM; Nunnerley, HB; Williams, R, 1982) |
| "Thirteen patients with functioning carcinoid syndrome and hepatic metastases were surgically treated." | ( Adson, MA; Martin, JK; Moertel, CG; Schutt, AJ, 1983) |
| "We treated nine patients who had carcinoid tumors of the small intestine, six of whom had the carcinoid syndrome, with daily intramuscular doses of leukocyte interferon--3 X 10(6) U per day for one month and 6 X 10(6) U per day for another two months." | ( Alm, G; Funa, K; Oberg, K, 1983) |
| "Certainly in treatment of the carcinoid tumor surgery has a well-established curative and palliative potential." | ( Moertel, CG, 1983) |
| "Sixteen patients with metastatic carcinoid tumor and the malignant carcinoid syndrome were treated with combined cyclophosphamide and methotrexate therapy in a regimen previously described as highly effective." | ( Moertel, CG; O'Connell, MJ; Reitemeier, RJ; Rubin, J, 1984) |
| "Eight patients with metastatic carcinoid tumors and the carcinoid syndrome were treated with gelatin foam embolization of the hepatic arterial tree." | ( Bengmark, S; Lunderquist, A; Mårtensson, H; Nobin, A; Owman, T; Sandén, G, 1984) |
| "Seven patients with metastasized midgut carcinoids were treated with intravenous infusion of dacarbazine [dimethyltriazenoimidazole carboxamide (DTIC)] (650 mg/m2) every 4 wk." | ( Leonhardt, U; Ramadori, G; Ritzel, U; Stöckmann, F, 1995) |
| "Fifty-five patients with metastatic carcinoid tumor were treated with the long-acting somatostatin analogue octreotide." | ( Janson, ET; Oberg, K, 1993) |
| "These data, particularly in respect to carcinoid tumors, are encouraging, especially since serious complications from treatment were limited." | ( Andreyev, HJ; Badve, SS; Cunningham, D; Iveson, A; Nicolson, MC; Nicolson, V; Norman, AR; Scott-Mackie, P, 1995) |
| "The frequency of invasive carcinoids after recovery (4/23) differed only slightly from that seen after treatment for 24 weeks (5/21)." | ( Ahlman, H; Dahlström, A; Modlin, IM; Nilsson, O; Theodorsson, E; Wängberg, B, 1995) |
| "Of the 21 patients who had carcinoid tumours, 11 were previously untreated and two achieved a response (18%, 95% CI = 2-52%)." | ( Lacave, AJ; Lips, CJ; Neijt, JP; Sahmoud, T; Splinter, TA; Taal, BG; Veenhof, CH, 1995) |
| "Of 176 ileal carcinoid patients, 4 were initially diagnosed and treated as having Crohn's; their mean age was 51." | ( Feldman, JM; Hsu, EY; Lichtenstein, GR, 1997) |
| "In spite of late diagnosis of carcinoid and significant acceleration of respiratory decompensation symptoms after the diagnosis the attempt of surgical therapy was appropriate but unsuccessful." | ( Andrzejak, R; Bochnia, M; Krajewski, E; Mydłowski, R; Orłowski, T, 1997) |
| "Patients with advanced metastatic carcinoid tumors who have disease progression despite conventional therapy are left with few therapeutic options." | ( Anthony, LB; Blair, TK; Chapman, WC; Drougas, JG; Lopez, RR; Mazer, M; Meranze, S; Pinson, CW; Webb, L; Wright, JK, 1998) |
| "A symptomatic patient with carcinoid liver metastases, unresponsive to chemotherapy combined with interferon-alpha, was subsequently treated with 131I-MIBG." | ( Bomanji, JB; Ell, PJ; Ledermann, JA; Prvulovich, EM; Stein, RC; Taylor, I, 1998) |
| "We report herein a case of rectal carcinoid with multiple liver metastasis successfully treated with hepatic arterial infusion of methotrexate (MTX) and 5-fluorouracil (5-FU)." | ( Idezuki, Y; Ishida, H; Nakada, H; Suzuki, T; Tada, M; Takeuchi, I, 1999) |
| "Treatment of a patient with carcinoid metastases in the liver is discussed." | ( Adamyan, A; Gumargalieva, K; Guseinov, E; Horák, D; Kokov, L; Skuba, N; Tchjao, A; Titova, M; Trostenyuk, N; Tsvirkun, V; Vishnevskii, V, 2000) |
| "Additional therapy of the gastric carcinoid was not necessary." | ( Gerl, H; Lochs, H; Rickes, S, 2000) |
| "The best therapy of the gastric carcinoids type 1, which are the most frequently gastric carcinoids, is endoscopic tumour removal." | ( Gerl, H; Lochs, H; Rickes, S, 2000) |
| "At The Netherlands Cancer Institute 34 carcinoid patients with no or insufficient uptake were treated with escalating doses of unlabelled ('cold') MIBG." | ( Boot, H; Hoefnagel, CA; Sivro, F; Taal, BG; Valdes Olmos, RA, 2000) |
| "A 78-year-old woman suffering from a carcinoid of the small intestine with multiple metastases in the liver as well as mesenteric and supraclavicular lymph node metastases was treated with this therapy after the disease had progressed under other chemotherapy options employed years previously." | ( Cybulla, M; Otte, A; Weiner, SM, 2001) |
| "A 39-year-old white man with metastatic carcinoid tumor tolerated treatment with subcutaneous long-acting octreotide monthly and interferon alfa 6 million units 3 times weekly for 6 months." | ( Choudhury, AM; Tanvetyanon, T, 2004) |
| "In our patient with metastatic carcinoid tumor, treatment with zoledronic acid and interferon alfa was associated with symptomatic hypocalcemia and acute renal failure." | ( Choudhury, AM; Tanvetyanon, T, 2004) |
| "Non-small-cell lung cancer or carcinoid pT1-4, N0-2, M0 patients treated by R0 surgical resection alone were imaged with computed tomography scan and PET within 90 days before surgery." | ( Akhurst, T; Bains, MS; Downey, RJ; Gonen, M; Larson, S; Rusch, V; Vincent, A, 2004) |
| "BON cells, a novel human carcinoid cell line that produces and secretes NT peptide and expresses the gene encoding NT (designated NT/N), were treated with ethidium bromide (EB; 0." | ( Evers, BM; Greeley, GH; Hellmich, MR; Li, J; Li, N; Rajaraman, S; Townsend, CM; Wang, Q; Wang, X, 2005) |
| "Twenty-one patients with metastatic carcinoid tumors were treated with docetaxel." | ( Clark, JW; Fuchs, CS; Kim, H; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, K; Vincitore, M, 2004) |
| "Twenty-one patients with metastatic carcinoid tumors were treated with docetaxel, administered at a dose of 75 mg/m2 every three weeks." | ( Clark, JW; Fuchs, CS; Kim, H; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, K; Vincitore, M, 2004) |
| "We report a case of a rectal carcinoid tumor that was treated using endoscopic resection." | ( Abós, MD; Banzo, J; Galofré, G; Mañé, S; Prats, E; Razola, P; Ubieto, MA; Vidal-Sicat, S, 2005) |
| "Of the patients with type 1 carcinoid, 3 had no specific treatment, 40 were treated with endoscopic or surgical excision (in 10 cases combined with antrectomy), 7 underwent total gastrectomy, and 1 underwent proximal gastric resection." | ( Ahlman, H; Ahrén, B; Borch, K; Falkmer, S; Granérus, G; Grimelius, L, 2005) |
| "Optimal treatments for metastatic carcinoid tumor remain undefined, and the role of chemotherapy for symptomatic patients with progressive disease is uncertain." | ( Catalano, P; Haller, DG; Lipsitz, S; Mailliard, JA; Sun, W, 2005) |
| "Six patients with midgut carcinoid metastases were examined with 11C-5-HTP PET before and 1 h after oral administration of 100 or 200 mg of CD." | ( Bergström, M; Eriksson, B; Långström, B; Lu, L; Oberg, K; Orlefors, H; Sundin, A, 2006) |
| "This is the first report of a severe carcinoid crisis developed after receptor radionuclide therapy with 90Y-DOTATOC administered in a patient affected by liver metastases from bronchial neuroendocrine tumor (atypical carcinoid)." | ( Bartolomei, M; Bodei, L; Davì, MV; Falconi, M; Ferdeghini, M; Francia, G; Lo Cascio, V; Oliani, C; Paganelli, G; Reghellin, D; Scilanga, L, 2006) |
| "The prognosis and treatment of carcinoids vary based on location and histology, and therapy must be tailored to each patient." | ( Chen, H; Sippel, RS, 2006) |
| "Reports of parotid carcinoid tumors during the past 30 years have described the presence of nonparotid primary carcinoid tumors (usually gastrointestinal) that had been diagnosed and treated several years prior to the presentation of the parotid lesion." | ( Kidd, M; Modlin, IM; Shapiro, MD, 2006) |
| "Cytoreductive therapy for metastatic carcinoid provides symptomatic relief and improvement in overall survival." | ( Alvarado, MD; Jensen, EH; Kvols, L; Lewis, JM; Malafa, M; McLoughlin, JM; Shibata, D; Yeatman, T, 2007) |
| "Effective systemic therapy options for carcinoid tumors are lacking." | ( Abbruzzese, JL; Ajani, JA; Ellis, L; Hess, K; Rashid, A; Szklaruk, J; Xie, K; Yao, JC; Yeung, SC; Zhang, JX, 2007) |
| "Cells of the human bronchial carcinoid cell line NCI-H727 and the human pancreatic carcinoid cell line BON-1 were treated with increasing concentrations of imatinib using standard procedures to assess in vitro growth-inhibitory activity." | ( Abbruzzese, JL; Ajani, JA; Ellis, L; Hess, K; Rashid, A; Szklaruk, J; Xie, K; Yao, JC; Yeung, SC; Zhang, JX, 2007) |
| "We report a case of atypical thymic carcinoid that responded to neoadjuvant therapy with octreotide and sunitinib, an oral multikinase inhibitor." | ( Dham, A; Dudek, AZ; Truskinovsky, AM, 2008) |
| "A case of testicular carcinoid within our clinic prompted us to review previous reports; all the cases found were assessed for patient and tumour characteristics, diagnostic tools used, treatment and prognosis." | ( Delaere, KP; Stroosma, OB, 2008) |
| "Three patients with a primary carcinoid were treated with adjuvant chemotherapy (two) or radiotherapy (one), with unknown results." | ( Delaere, KP; Stroosma, OB, 2008) |
| "There are very few ileal carcinoid cell lines available for in vitro studies to analyze new drugs that could be effective in treating patients with metastatic tumors." | ( Erickson, LA; Hobday, T; Jin, L; Leontovich, AA; Lloyd, RV; Ruebel, KH; Stilling, GA; Tanizaki, Y; Zhang, H; Zhang, S, 2007) |
| "Eighteen patients with midgut carcinoid treated with alpha interferon were included in the study." | ( Janson, ET; Larsson, G, 2008) |
| "Gastrointestinal and pulmonary carcinoid cells were treated with either VPA or SBHA and lithium chloride for up to 48 hours." | ( Adler, JT; Chen, H; Hottinger, DG; Kunnimalaiyaan, M, 2009) |
| "The treatment of the human pancreas carcinoid cell line BON and the mouse insulinoma cell line beta-TC-3 with EGFR and COX-2 inhibitors (monotherapy and combined therapy) resulted in a significant, dose-dependent reduction of cell viability coupled with increased apoptosis." | ( Bergmann, F; Breinig, M; Ehemann, V; Esposito, I; Fischer, L; Friess, H; Herpel, E; Höpfner, M; Kern, MA; Kleeff, J; Köhler, C; Rieker, RJ; Schirmacher, P, 2009) |
| "We investigated a novel treatment for carcinoid cell growth based on pharmacologic Raf-1 activation using the compound tautomycin (TTY)." | ( Adler, JT; Chen, H; Ju, J; Kunnimalaiyaan, M; Li, W; Luo, Y; Pinchot, SN; Shen, B, 2009) |
| "Human carcinoid cells were treated with TTY for 48 hours." | ( Adler, JT; Chen, H; Ju, J; Kunnimalaiyaan, M; Li, W; Luo, Y; Pinchot, SN; Shen, B, 2009) |
| "Human carcinoid BON cells were treated in vitro with LY294002, a PI3-kinase inhibitor, or transfected with Akt1 siRNA." | ( Chen, H; Kunnimalaiyaan, M; Pitt, SC, 2009) |
| "Human pulmonary carcinoid NCI-H727 cells were treated with LY294002 (0 to 100 microM), a well-known PI3K inhibitor, or transfected with Akt1 small interfering RNA (75 nM)." | ( Chen, H; Kunnimalaiyaan, M; Pitt, SC, 2009) |
| "Treating carcinoid cells with MG-132 resulted in growth inhibition, a dose-dependent inhibition of CgA and ASCL1, as well as an increase in the levels of cleaved PARP and cleaved caspase-3." | ( Chen, H; Chen, JY; Cook, MR; Kunnimalaiyaan, M; Pinchot, SN, 2010) |
| "In patients with carcinoid disease, urinary concentration of the serotonin metabolite 5-hydroxyindole acetic acid (5-HIAA) is currently used to monitor disease progression or response to treatment as it is the metabolic end-product resulting from free and stored serotonin turnover." | ( Allen, K; Brown, H; Degg, T; Keevil, BG; Miller, AG, 2010) |
| "Thirty-one patients with advanced carcinoid tumors were treated with 2ME2, administered orally at a dose of 1,000 mg four times daily." | ( Abrams, TA; Blaszkowsky, LS; Chan, JA; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Regan, E; Sidor, C; Zhu, AX, 2011) |
| "Human gastrointestinal carcinoid (BON) cell growth after hesperetin treatment was assessed with a 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide assay." | ( Chen, H; Kunnimalaiyaan, M; Pinchot, SN; Zarebczan, B, 2011) |
| "Treatment of carcinoid cells with RESV resulted in up-regulation of the Notch signaling pathway as measured by suppression of its downstream target achaete-scute complex-like 1." | ( Chen, H; Cook, MR; Jaskula-Sztul, R; Kunnimalaiyaan, M; Ning, L; Peters, NR; Pinchot, SN, 2011) |
| "Three patients with type I gastric carcinoid in autoimmune gastritis were administered, after informed consent and ethic committee approval, with a vaccine against gastrin 17 (G17), a synthetic peptide that stimulates specific and high-affinity anti-G17 antibodies, and followed up endoscopically and clinically for a mean of 36 months." | ( Basso, D; Betterle, C; Cazzagon, N; Farinati, F; Maddalo, G; Martini, C; Mescoli, C; Nitti, D; Rugge, M; Tieppo, C; Zorzetto, V, 2011) |
| "Gastric ECL-cell hyperplasia and carcinoids (ECLoma) develop after 1 year in rats treated with omeprazole or 2 months in Mastomys treated with loxtidine." | ( Chen, D; Kidd, M; Modlin, IM; Vigen, RA; Zhao, CM, 2012) |
| "We report a case of gastrointestinal carcinoid with bilateral ovarian metastases in a 50-year-old female who received octreotide therapy followed by peptide receptor radionuclide therapy and surgery thereafter." | ( Bal, CS; Durgapal, P; Gupta, S; Reddy, RM; Singla, S, 2012) |
| "Gastric carcinoids in Mastomys were induced by loxtidine treatment." | ( Chen, D; Fossmark, R; Kidd, M; Kodama, Y; Modlin, IM; Vigen, RA; Viset, T; Waldum, H; Wang, TC; Zhao, CM, 2013) |
| "Chemotherapy is of limited value in carcinoids with low proliferation indices but may be useful in higher grade tumors." | ( Kidd, M; Modlin, I; Pavel, M, 2013) |
| "Bronchial carcinoids (BCs) are rare neuroendocrine tumors that are still orphans of medical treatment." | ( Ambrosio, MR; Andriolo, LG; Bellio, M; Cavallesco, NG; Degli Uberti, E; Gagliano, T; Gentilin, E; Molè, D; Rea, F; Schiavon, M; Tagliati, F; Zatelli, MC, 2013) |
| "Metastatic bronchial carcinoids are rare neoplasms, where efforts of medical treatment so far have been disappointing." | ( Antonodimitrakis, P; Crona, J; Eriksson, B; Fanola, I; Granberg, D; Lindholm, DP; Öberg, K, 2013) |
| "In a patient with a carcinoid crisis and ARDS refractory to conventional therapies, substantial hemodynamic and oxygenation improvements were observed following methylene blue administration." | ( Lewanczuk, R; Mullen, JC; Sidhu, S; Singh, G; Sobey, A; van Diepen, S; Zibdawi, M, 2013) |
| "Gastric carcinoids disappeared after a median length of treatment of 12 months." | ( Ciafardini, C; Conte, D; Fanetti, I; Massironi, S; Peracchi, M; Zilli, A, 2015) |
| "This study confirms that type-1 gastric carcinoids are a recurring disease and somatostatin analogues, administered on 12-month cycles, represent an effective treatment." | ( Ciafardini, C; Conte, D; Fanetti, I; Massironi, S; Peracchi, M; Zilli, A, 2015) |
| "Treatment of two carcinoid cell lines (BON and H727) with varying chrysin concentrations suppressed cell proliferation, while reducing expression of ASCL1 and the neuroendocrine biomarker chromogranin A (CgA), demonstrated by western blotting." | ( Chen, H; Dull, BZ; Eide, J; Jaskula-Sztul, R; Somnay, YR, 2015) |
| "In our experience, carcinoid tumor metastasis to the brain-whether because of tumor makeup or prior treatment-is unlikely to produce symptoms of new-onset carcinoid syndrome intraoperatively; however, the risk cannot be completely excluded." | ( Lanier, WL; Pasternak, JJ; Welch, TL, 2016) |
| "Patients with carcinoid tumors frequently could benefit from the pharmacologic treatment of depression and anxiety." | ( Brais, LK; Braun, IM; Chan, JA; Dutton, T; Kulke, MH; Meyer, FL; Minden, SL; Shi, DD; Yuppa, DP, 2017) |
| "Patients were stratified by carcinoid type (typical vs atypical) and line of study treatment (first line vs others)." | ( Baudin, E; Berruti, A; Brizzi, MP; Buikhuisen, W; Damiano, V; De Castro, J; Do Cao, C; Ferolla, P; Gislimberti, G; Grohé, C; Grønbæk, H; Léna, H; Lombard-Bohas, C; Mansoor, W; Mazieres, J; Meyer, T; Minotti, V; Öberg, K; Reed, N; Singh, N; Stankovic, M; Tiseo, M, 2017) |
| "Bronchopulmonary carcinoids are low-grade tumors for which the standard treatment is surgical resection." | ( Maki, Y; Nakata, K; Nishimura, R; Sugawara, Y; Sugimoto, R; Teramoto, N; Ueno, T; Yamashita, M, 2019) |